MCL Clinical Trials
1230 trials from ClinicalTrials.gov. Recruiting trials shown first.
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
COMPLETEDNCT00407303·PHASE1 / PHASE2·Gemin X·24 enrolled
Obatoclax mesylateBortezomib
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
TERMINATEDNCT00383565·PHASE2·National Cancer Institute (NCI)·9 enrolled
romidepsin
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
COMPLETEDNCT00352443·PHASE1·SWOG Cancer Research Network·66 enrolled
everolimuslapatinib ditosylate
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
COMPLETEDNCT00509379·PHASE2·Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·48 enrolled
RituximabVELCADE
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
COMPLETEDNCT00376961·PHASE2·SWOG Cancer Research Network·68 enrolled
rituximabbortezomibcyclophosphamidedoxorubicin hydrochlorideprednisone+1 more
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
COMPLETEDNCT00410657·PHASE2·Fred Hutchinson Cancer Center·53 enrolled
alemtuzumabmethylprednisoloneprednisoneflow cytometryimmunologic technique+1 more
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
COMPLETEDNCT00334438·PHASE1·UNC Lineberger Comprehensive Cancer Center·12 enrolled
rituximabbortezomibyttrium Y 90 ibritumomab tiuxetanIndium 111 ibritumomab tiuxetan
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
COMPLETEDNCT00387959·PHASE2·Memorial Sloan Kettering Cancer Center·17 enrolled
filgrastimrituximabcyclophosphamidecyclosporinefludarabine phosphate+4 more
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
COMPLETEDNCT00416312·Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·9 enrolled
Patient-specific dosimetryconventional dosimetry
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
COMPLETEDNCT00536601·NA·Roswell Park Cancer Institute·174 enrolled
etoposidecyclophosphamidecarmustinemelphalanbusulfan+5 more
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
COMPLETEDNCT00513955·PHASE2·University Hospital Plymouth NHS Trust·50 enrolled
bortezomibcyclophosphamidedoxorubicin hydrochlorideprednisolonevincristine sulfate+2 more
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETEDNCT00293345·PHASE1·National Cancer Institute (NCI)·30 enrolled
gemcitabine hydrochloridetriapine
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
COMPLETEDNCT00408681·NA·Fred Hutchinson Cancer Center·20 enrolled
lithium carbonatelaboratory biomarker analysis
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
COMPLETEDNCT00310037·PHASE2·Alliance for Clinical Trials in Oncology·151 enrolled
bortezomib
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
TERMINATEDNCT00827099·PHASE2·Northside Hospital, Inc.·5 enrolled
anti-thymocyte globulinfludarabine phosphateMelphalanmycophenolate mofetiltacrolimus+1 more
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
COMPLETEDNCT00376922·NA·Wake Forest University Health Sciences·65 enrolled
music therapy
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
TERMINATEDNCT00324324·PHASE3·OHSU Knight Cancer Institute·240 enrolled
moxifloxacin hydrochloridePlacebo
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
WITHDRAWNNCT00085449·PHASE1 / PHASE2·Alliance for Clinical Trials in Oncology
alemtuzumabcyclosporinefludarabine phosphatemelphalanmycophenolate mofetil+2 more
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
TERMINATEDNCT00354185·PHASE1·National Cancer Institute (NCI)·36 enrolled
tanespimycinbelinostatlaboratory biomarker analysispharmacological study
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
COMPLETEDNCT00132015·PHASE2·National Institutes of Health Clinical Center (CC)·37 enrolled
tanespimycin
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
COMPLETEDNCT00357084·PHASE2·Fred Hutchinson Cancer Center·53 enrolled
methotrexatemethylprednisoloneprednisone
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
COMPLETEDNCT00571493·PHASE1 / PHASE2·University of Nebraska·42 enrolled
BortezomibBEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
COMPLETEDNCT00343798·PHASE1·Fred Hutchinson Cancer Center·23 enrolled
cyclophosphamidefludarabine phosphatecyclosporinemycophenolate mofetilex-vivo umbilical cord blood expansion+4 more
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
COMPLETEDNCT00348985·PHASE1·National Cancer Institute (NCI)·55 enrolled
belinostatbortezomibpharmacological study
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
COMPLETEDNCT00109824·PHASE1·National Cancer Institute (NCI)·42 enrolled
decitabinevalproic acidpharmacological studylaboratory biomarker analysis
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
COMPLETEDNCT00299182·PHASE1 / PHASE2·M.D. Anderson Cancer Center·50 enrolled
AMG 531RituximabCyclophosphamideVincristineDoxorubicin+4 more
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
COMPLETEDNCT00281814·The Cleveland Clinic·36 enrolled
psychosocial assessment and care
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
TERMINATEDNCT00275262·PHASE2·Abbott·25 enrolled
Leuprolide acetate depot (LAD) 11.25 mg 3 MonthMatched placebo
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
COMPLETEDNCT00281801·Case Comprehensive Cancer Center·168 enrolled
psychosocial assessment and careQuality of Life Assessments
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
TERMINATEDNCT00281879·PHASE2·OHSU Knight Cancer Institute·200 enrolled
anti-thymocyte globulinfilgrastimbusulfancarmustinecyclophosphamide+12 more